Annual report pursuant to Section 13 and 15(d)

Income Taxes (Narrative) (Details)

v3.23.3
Income Taxes (Narrative) (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Tax Expense (Benefit) [Line Items]      
Increase in deferred tax assets related to change in recognition of research and development expense $ 9,800,000    
Net impact to income tax benefit related change in recognition of research and development expense $ 0    
Unrecognized tax benefits   $ 0 $ 0
Minimum [Member]      
Income Tax Expense (Benefit) [Line Items]      
Operating loss carryforwards, expiration date   Dec. 31, 2024  
Maximum [Member]      
Income Tax Expense (Benefit) [Line Items]      
Operating loss carryforwards, expiration date   Dec. 31, 2043  
Tax Period 2038 To 2043 [Member] | U.S. federal research and development tax credit carryforwards [Member]      
Income Tax Expense (Benefit) [Line Items]      
Tax credit carryforward   $ 8,300,000  
Tax Period 2038 To 2043 [Member] | Minimum [Member] | U.S. federal research and development tax credit carryforwards [Member]      
Income Tax Expense (Benefit) [Line Items]      
Tax credit carryforward, expiration date   Dec. 31, 2038  
Tax Period 2038 To 2043 [Member] | Maximum [Member] | U.S. federal research and development tax credit carryforwards [Member]      
Income Tax Expense (Benefit) [Line Items]      
Tax credit carryforward, expiration date   Dec. 31, 2043  
Domestic [Member]      
Income Tax Expense (Benefit) [Line Items]      
Operating loss carryforwards   $ 140,500,000  
Domestic [Member] | Minimum [Member]      
Income Tax Expense (Benefit) [Line Items]      
Operating loss carryforwards, expiration date   Dec. 31, 2024  
Domestic [Member] | Maximum [Member]      
Income Tax Expense (Benefit) [Line Items]      
Operating loss carryforwards, expiration date   Dec. 31, 2038  
Domestic [Member] | Tax Period 2024 To 2043 [Member]      
Income Tax Expense (Benefit) [Line Items]      
Operating loss carryforwards   $ 29,700,000  
Domestic [Member] | Indefinite [Member]      
Income Tax Expense (Benefit) [Line Items]      
Operating loss carryforwards   110,800,000  
State [Member]      
Income Tax Expense (Benefit) [Line Items]      
Operating loss carryforwards   62,400,000  
State [Member] | Tax Period 2024 To 2043 [Member]      
Income Tax Expense (Benefit) [Line Items]      
Operating loss carryforwards   35,200,000  
State [Member] | Indefinite [Member]      
Income Tax Expense (Benefit) [Line Items]      
Operating loss carryforwards   27,200,000  
Foreign [Member] | Indefinite [Member]      
Income Tax Expense (Benefit) [Line Items]      
Operating loss carryforwards   63,000,000.0  
United States [Member]      
Income Tax Expense (Benefit) [Line Items]      
Valuation allowance   62,100,000 42,200,000
Valuation allowance, deferred tax asset, change in amount   19,900,000  
U.K. [Member] | The Female Health Company Limited [Member]      
Income Tax Expense (Benefit) [Line Items]      
Valuation allowance   3,200,000 3,200,000
U.K. [Member] | The Female Health Company UK [Member]      
Income Tax Expense (Benefit) [Line Items]      
Valuation allowance   0 0
U.K. [Member] | Veru Biopharma UK Limited [Member]      
Income Tax Expense (Benefit) [Line Items]      
Valuation allowance   $ 300,000 $ 300,000